Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia.
about
Opportunities for model-based precision dosing in the treatment of sickle cell anemia.Population Pharmacokinetic and Exposure-Response Analyses of Prasugrel in Pediatric Patients with Sickle Cell Anemia.Clinical Trial Simulations and Pharmacometric Analysis in Pediatrics: Application to Inhaled Loxapine in Children and Adolescents.Hydroxycarbamide in children with sickle cell anaemia after first-dose vs. chronic therapy: pharmacokinetics and predictive models for drug exposure.
P2860
Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Development of a pharmacokinet ...... dren with sickle cell anaemia.
@ast
Development of a pharmacokinet ...... dren with sickle cell anaemia.
@en
type
label
Development of a pharmacokinet ...... dren with sickle cell anaemia.
@ast
Development of a pharmacokinet ...... dren with sickle cell anaemia.
@en
prefLabel
Development of a pharmacokinet ...... dren with sickle cell anaemia.
@ast
Development of a pharmacokinet ...... dren with sickle cell anaemia.
@en
P2093
P2860
P356
P1476
Development of a pharmacokinet ...... dren with sickle cell anaemia.
@en
P2093
Patrick T McGann
Russell E Ware
Tomoyuki Mizuno
P2860
P304
P356
10.1111/BCP.12851
P407
P50
P577
2015-11-28T00:00:00Z